Skip to main content
Premium Trial:

Request an Annual Quote

Andy Watson, Anthony Scarpello

Empire Genomics has appointed Andy Watson as CEO and Anthony Scarpello as chief commercialization officer. Watson was previously CEO at Genturi, a genomics technology startup. He was also chief commercial officer at RainDance Technologies, which was acquired by Bio-Rad Laboratories. Prior to Raindance, he was the vice president of SOLiD sequencing product management at Life Technologies, now part of Thermo Fisher Scientific. He also previously led the capillary electrophoresis sequencing business for Applied Biosystems, which became part of Life Technologies.

Scarpello was promoted from vice president of sales and business development to CCO. He joined Empire Genomics in 2009, and previously held numerous senior management roles with Enzo Life Sciences.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.